Celldex (CLDX) Stock Forecast & Price Target

Compare

1,143 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CLDX Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Celldex

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CLDX Stock 12 Month Forecast

Average Price Target

$61.00

▲(210.12%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is $61.00 with a high forecast of $80.00 and a low forecast of $38.00. The average price target represents a 210.12% change from the last price of $19.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.71,25.270769230769233,29.831538461538464,34.392307692307696,38.95307692307692,43.51384615384616,48.074615384615385,52.635384615384616,57.19615384615385,61.75692307692308,66.31769230769231,70.87846153846155,75.43923076923076,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.71,23.80923076923077,26.908461538461538,30.00769230769231,33.10692307692308,36.206153846153846,39.30538461538462,42.40461538461538,45.503846153846155,48.60307692307693,51.70230769230769,54.80153846153846,57.900769230769235,{"y":61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.71,22.04,23.37,24.7,26.03,27.36,28.689999999999998,30.02,31.35,32.68,34.01,35.34,36.67,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.35,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.33,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$61.00

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$19.5

Hold

-0.86%

Downside

Reiterated

06/05/25

Celldex's strong balance sheet and slight positive technical momentum are overshadowed by its unprofitability and negative cash flow. The lack of earnings call insights and corporate events further limits the stock's attractiveness. Improvement in profitability and cash flow could enhance the stock's potential.

Derek ArchilaWells Fargo

Wells Fargo

$44

Buy

123.69%

Upside

Reiterated

05/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sam SlutskyLifeSci Capital

LifeSci Capital

$74

Buy

276.21%

Upside

Reiterated

05/20/25

Celldex's Strategic Advancements and Promising Pipeline Drive Buy Rating

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$67

Buy

240.62%

Upside

Reiterated

05/19/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)

Edward NashCanaccord Genuity

Canaccord Genuity

$64

Buy

225.37%

Upside

Reiterated

05/11/25

Celldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

Thomas SmithLeerink Partners

Leerink Partners

$78

Buy

296.54%

Upside

Reiterated

05/09/25

Celldex's Strategic Advancements and Promising Clinical Developments Drive Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/09/25

Celldex's Promising Pipeline and Strong Financial Position Justify Buy Rating

Trung HuynhUBS

UBS

$44→$38

Buy

93.19%

Upside

Reiterated

05/09/25

Celldex price target lowered to $38 from $44 at UBSCelldex price target lowered to $38 from $44 at UBS

Judah FrommerMorgan Stanley

Morgan Stanley

$46→$43

Buy

118.61%

Upside

Reiterated

05/09/25

Celldex: Strong Financials and Promising Clinical Developments Support Buy Rating

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$80

Buy

306.71%

Upside

Reiterated

05/06/25

Promising Phase 2 Results for Celldex's Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating

Richard Law CFAGoldman Sachs

Goldman Sachs

$42→$36

Hold

83.02%

Upside

Reiterated

02/28/25

Celldex Therapeutics (CLDX) PT Lowered to $36 at Goldman SachsGoldman Sachs analyst Richard Law lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $36.00 (from $42.00) while maintaining a Neutral rating.

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$58

Buy

194.87%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)

Yatin SunejaGuggenheim

Guggenheim

$90

Buy

357.55%

Upside

Reiterated

01/08/25

Guggenheim on Celldex Therapeutics (CLDX): CLDX Remains Leader In The Mast Cell SpaceGuggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on Celldex Therapeutics (NASDAQ: CLDX)

David LebowitzCiti

Citi

$70

Buy

255.87%

Upside

Reiterated

01/08/25

Buy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper's Delayed Competition

Andy ChenWolfe Research

Wolfe Research

$51

Hold

159.28%

Upside

Downgraded

09/26/24

Celldex barzolvolimab data above expectations, says Wolfe ResearchCelldex barzolvolimab data above expectations, says Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$19.5

Hold

-0.86%

Downside

Reiterated

06/05/25

Derek ArchilaWells Fargo

Wells Fargo

$44

Buy

123.69%

Upside

Reiterated

05/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sam SlutskyLifeSci Capital

LifeSci Capital

$74

Buy

276.21%

Upside

Reiterated

05/20/25

Celldex's Strategic Advancements and Promising Pipeline Drive Buy Rating

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$67

Buy

240.62%

Upside

Reiterated

05/19/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)

Edward NashCanaccord Genuity

Canaccord Genuity

$64

Buy

225.37%

Upside

Reiterated

05/11/25

Celldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

Thomas SmithLeerink Partners

Leerink Partners

$78

Buy

296.54%

Upside

Reiterated

05/09/25

Celldex's Strategic Advancements and Promising Clinical Developments Drive Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/09/25

Celldex's Promising Pipeline and Strong Financial Position Justify Buy Rating

Trung HuynhUBS

UBS

$44→$38

Buy

93.19%

Upside

Reiterated

05/09/25

Celldex price target lowered to $38 from $44 at UBSCelldex price target lowered to $38 from $44 at UBS

Judah FrommerMorgan Stanley

Morgan Stanley

$46→$43

Buy

118.61%

Upside

Reiterated

05/09/25

Celldex: Strong Financials and Promising Clinical Developments Support Buy Rating

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$80

Buy

306.71%

Upside

Reiterated

05/06/25

Promising Phase 2 Results for Celldex's Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating

Richard Law CFAGoldman Sachs

Goldman Sachs

$42→$36

Hold

83.02%

Upside

Reiterated

02/28/25

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$58

Buy

194.87%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)

Yatin SunejaGuggenheim

Guggenheim

$90

Buy

357.55%

Upside

Reiterated

01/08/25

David LebowitzCiti

Citi

$70

Buy

255.87%

Upside

Reiterated

01/08/25

Buy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper's Delayed Competition

Andy ChenWolfe Research

Wolfe Research

$51

Hold

159.28%

Upside

Downgraded

09/26/24

Celldex barzolvolimab data above expectations, says Wolfe ResearchCelldex barzolvolimab data above expectations, says Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

1 Month

xxx

Success Rate

13/23 ratings generated profit

Average Return

+5.90%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +5.90% per trade.

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+11.48%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +11.48% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

8/16 ratings generated profit

Average Return

+81.19%

reiterated a buy rating 19 days ago

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +81.19% per trade.

2 Years

xxx

Success Rate

6/16 ratings generated profit

Average Return

+56.41%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +56.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLDX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CLDX has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLDX average Analyst price target in the past 3 months is 61.00.

Each month's total comprises the sum of three months' worth of ratings.

CLDX Financial Forecast

CLDX Earnings Forecast

Next quarter’s earnings estimate for CLDX is -$0.85 with a range of -$0.95 to -$0.76. The previous quarter’s EPS was -$0.81. CLDX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CLDX has Outperformed its overall industry.

CLDX Sales Forecast

Next quarter’s sales forecast for CLDX is $1.03M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $695.00K. CLDX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year CLDX has Outperformed its overall industry.

CLDX Stock Forecast FAQ

What is CLDX’s average 12-month price target, according to analysts?

Based on analyst ratings, Celldex Therapeutics’s 12-month average price target is 61.00.

What is CLDX’s upside potential, based on the analysts’ average price target?

Celldex Therapeutics has 210.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CLDX a Buy, Sell or Hold?

Celldex Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Celldex Therapeutics’s price target?

The average price target for Celldex Therapeutics is 61.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $38.00. The average price target represents 210.12% Increase from the current price of $19.67.

What do analysts say about Celldex Therapeutics?

Celldex Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CLDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Celldex (CLDX) Stock Forecast & Price Target

CLDX Analyst Ratings

CLDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Celldex

CLDX Analyst Recommendation Trends

CLDX Financial Forecast

CLDX Earnings Forecast

CLDX Sales Forecast

CLDX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts